QLTI-05. EUROPEAN NEURO-ONCOLOGY QUALITY ASSURANCE (ENOQUA): AN EORTC BRAIN TUMOR GROUP STUDY

Abstract INTRODUCTION Neuro-Oncology, a complex and multidisciplinary field that is relatively recent, lacks well-established quality assurance measures and standards for patient care. METHODS We assessed the performance of 14 potential quality indicators across 19 EORTC Neuro-Oncology centers to validate these indicators as effective measures of quality. For each center, we abstracted records from 20 patients diagnosed with glioblastoma in 2018 who were not enrolled in an investigational study. We tested associations between patient survival, center characteristics, and the performance of these quality measures. RESULTS Most centers met several standard requirements, suggesting their potential acceptance for prospective validation. IDH expression data was universally recorded in the patients’ chart. Performing MRI within 72 hours of surgery and providing patient education for chemotherapy correlated with improved overall survival (OS). Standards met in the majority of centers were the presence of a multidisciplinary plan, a radiation plan and the extent of surgery recorded in the chart, as well as the referral for radiation within six weeks of diagnosis. Preliminary results indicate that academic centers outperformed others in most measures, although analysis is ongoing. Performance varied significantly across centers; some standards were consistently met poorly, highlighting areas needing improvement. Lack of universal acceptance of certain practices as necessary and/or important may render some standards inappropriate for further development. Final analysis will be presented at the meeting. CONCLUSION We are developing a comprehensive set of standards and measures for QA in neuro-oncology, which will require future prospective validation.